Legendary Bio and Johnson and Johnson co-developed multi-meeloma drug JNJ-68284528 to be recognized as A preferred drug by EMA
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Kingsley Biotech LimitedCompany(http://announced that its subsidiary Legendary Bio and JohnsonPharmaceuticals(http://subsidiary, Janssen Pharmaceuticals, have jointly developed and commercialized thedrug(http://JNJ-68284528 (LCAR-B38M) for the EuropeanMedicines(http://(EMA) (MA)JNJ-68284528 is a B-cell mature antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, and is currently rapidly conducting clinicaltrial trial series(http://in China and the United States Upon this recognition, Product (http:// will receive EMA support in clinical development and are expected to be on the market at an early date This is the first CAR-T product in China to be certified by the European Medicines Agency (EMA) Priority Drug Identification (PRIME)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
